0000-0003-4039-1491 Employment
-
Aurigene Discovery Technologies Limited CEO
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (57)
- Ternary complex formation of AFN-1252 with Acinetobacter baumannii FabI and NADH: Crystallographic and biochemical studies Save
- A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy Save
- ODM-203, a selective inhibitor of FGFR and VEGFR, shows strong antitumor activity, and induces antitumor immunity Save
- Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways Save
- Anti-PD-L1 peptide improves survival in sepsis Save
- Small-molecule antagonists of the immune checkpoint pathways: Concept to clinic Save
- The multi-kinase inhibitor Debio 0617B reduces maintenance and self-renewal of primary human AML CD34+ stem/progenitor cells Save
- Debio 0617B inhibits growth of STAT3-driven solid tumors through combined inhibition of JAK, SRC, and class III/V receptor tyrosine kinases Save
- Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion Save
- AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei - Crystal structure, mode of action, and biological activity Save